Alector, Inc. (NASDAQ:ALEC) Shares Acquired by Creative Planning

Creative Planning grew its position in Alector, Inc. (NASDAQ:ALEC) by 54.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 19,117 shares of the company’s stock after acquiring an additional 6,723 shares during the quarter. Creative Planning’s holdings in Alector were worth $89,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ALEC. Federated Hermes Inc. raised its stake in shares of Alector by 4.1% during the second quarter. Federated Hermes Inc. now owns 68,538 shares of the company’s stock valued at $311,000 after purchasing an additional 2,709 shares during the period. Susquehanna Fundamental Investments LLC increased its stake in shares of Alector by 2.8% in the second quarter. Susquehanna Fundamental Investments LLC now owns 129,664 shares of the company’s stock worth $589,000 after buying an additional 3,500 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Alector by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 112,920 shares of the company’s stock valued at $513,000 after acquiring an additional 3,790 shares during the last quarter. ProShare Advisors LLC grew its stake in Alector by 24.1% in the first quarter. ProShare Advisors LLC now owns 19,709 shares of the company’s stock worth $119,000 after purchasing an additional 3,827 shares in the last quarter. Finally, American International Group Inc. raised its stake in Alector by 13.0% during the first quarter. American International Group Inc. now owns 35,655 shares of the company’s stock valued at $215,000 after buying an additional 4,105 shares in the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Insider Activity

In related news, CEO Arnon Rosenthal sold 26,499 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the transaction, the chief executive officer now owns 1,948,746 shares in the company, valued at $9,509,880.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Alector news, insider Sara Kenkare-Mitra sold 13,926 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $67,958.88. Following the completion of the sale, the insider now directly owns 291,715 shares of the company’s stock, valued at approximately $1,423,569.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Arnon Rosenthal sold 26,499 shares of Alector stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total value of $129,315.12. Following the transaction, the chief executive officer now owns 1,948,746 shares in the company, valued at $9,509,880.48. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,722 shares of company stock valued at $232,883. Company insiders own 9.10% of the company’s stock.

Alector Stock Performance

Alector stock opened at $5.55 on Wednesday. The firm has a market capitalization of $543.51 million, a P/E ratio of -3.26 and a beta of 0.66. The company has a 50-day simple moving average of $5.10 and a 200-day simple moving average of $5.13. Alector, Inc. has a one year low of $3.66 and a one year high of $8.90.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.10. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The company had revenue of $15.34 million for the quarter, compared to analysts’ expectations of $16.33 million. As a group, sell-side analysts forecast that Alector, Inc. will post -1.9 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ALEC shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a research report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Alector in a research report on Thursday, November 7th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $17.75.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.